The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
27
Unnamed facility
Warsaw, Poland
Blood samples
Time frame: 5 weeks
Safety based on adverse events monitoring, physical examinations, vital sign evaluations, 12-lead ECGs and routine laboratory tests.
Time frame: 5 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.